Table 3 Duration of nephrotic syndrome, steroid therapy, laboratory, and echocardiographic data in cases with systolic dysfunction vs. cases without

Serum creatinine at the time of assessment (mg/dL)

0.8 ± 0.05

0.79 ± 0.04

0.56

Serum urea at the time of assessment (mg/dL)

14 ± 2

12 ± 3

0.66

Serum baseline cholesterol (mg/dL)

226 ± 12

232 ± 10

0.56

Serum cholesterol at the time of assessment (mg/dL)

177 ± 21

173 ± 20

0.72

Serum baseline albumin (gm/dL)

2.2 ± 0.1

2.3 ± 0.2

0.56

Serum albumin at the time of assessement (gm/dL)

2.4 ± 0.3

2.9 ± 0.1

< 0.001

Baseline urine P/C ratio

6 ± 0.9

5 ± 1

0.65

Urine P/C ratio at the time of assessment

3 ± 0.7

1.4 ± 0.4

< 0.001

Duration from onset of NS to time of assessment by echocardiography (weeks)

16 ± 1

14 ± 2

0.39

Duration of steroid therapy (weeks)

14.8 ± 2

15.9 ± 3

0.5

Dose of steroid (mg/kg/day)

2 ± 0

2 ± 0

0.9

Weight difference from the onset to time of assessment (kg)

2.2 ± 0.2

3.1 ± 0.3

< 0.001

3D LVEDV (ml)

61 ± 12

58 ± 22

0.45

3D EF (%)

77 ± 3.2

79 ± 4

0.40

FS (%)

46 ± 2

46 ± 3

0.23

GLS (%)

14 ± 3.2

18 ± 1.41

< 0.0001

E/e′

12 ± 2

8 ± 1.29

< 0.0001